Cineplex Inc. Announces Its October 2015 Dividend

TORONTO, ONTARIO -- (Marketwired) -- 10/20/15 -- Cineplex Inc. (TSX: CGX) announced today its cash dividend of $0.13 per share for the month of October 2015 payable on November 30, 2015, to shareholders of record on October 30, 2015.

Cineplex Inc. ("Cineplex") is one of Canada's leading entertainment companies and operates one of the most modern and fully digitized motion picture theatre circuits in the world. A top-tier Canadian brand, Cineplex operates numerous businesses including theatrical exhibition, food services, gaming, alternative programming (Front Row Centre Events), Cineplex Media, Cineplex Digital Solutions, Cineplex Digital Networks, and the online sale of home entertainment content through CineplexStore.com and on apps embedded in various electronic devices. Cineplex is also a joint venture partner in SCENE - Canada's largest entertainment loyalty program.

Cineplex is headquartered in Toronto, Canada, and operates 162 theatres with 1,652 screens from coast to coast, serving approximately 74 million guests annually through the following theatre brands: Cineplex Odeon, SilverCity, Galaxy Cinemas, Scotiabank Theatres, Cineplex Cinemas and Cineplex VIP Cinemas. Cineplex also owns and operates the UltraAVX, Poptopia, and Outtakes brands. Cineplex trades on the Toronto Stock Exchange under the symbol CGX. More information is available at Cineplex.com.

Further information can be found in the disclosure documents filed by Cineplex Inc. with the securities regulatory authorities, available at www.sedar.com.

Contacts:
Cineplex Inc.
Gord Nelson
Chief Financial Officer
(416) 323-6602

Cineplex Inc.
Pat Marshall
Vice President Communications and Investor Relations
(416) 323-6648

Source: Cineplex Inc.

You May Also Be Interested In

• BC.GAME Adds Support for CASHCAT as Robinhood Chain Activity Surges
• Quadient UK Open Locker Network Surpasses 3,000 Locations Nationwide
• Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)